France-based Sanofi (NASDAQ: SNY) reported Q2 2022 global sales of EUR 10.1 billion (USD 10.3 billion), marking an 8.1% year-on-year (YOY) increase in constant exchange rate (CER) terms. Growth was driven by the anti-allergy drug Dupixent (dupilumab) and strong performances in rare diseases, vaccines, and consumer healthcare.
Pharmaceuticals and Vaccines
- Pharmaceuticals: Sales rose 7.9% YOY to EUR 7.7 billion (USD 7.8 billion).
- Vaccines: Revenue increased 8.7% to EUR 1.2 billion (USD 1.2 billion), boosted by strong sales of Pentaxim in China.
- Consumer Healthcare: Sales grew 9.1% to EUR 1.3 billion (USD 1.3 billion).
Top Products
- Dupixent: Top-selling treatment with EUR 2.0 billion (USD 2.0 billion) in sales, up 43.4% YOY.
- Lantus (insulin glargine): Sales dropped 12.1% to EUR 600 million (USD 611 million).
- Aubagio (teriflunomide): Sales fell 2.2% to EUR 526 million (USD 536 million).
China Performance
- Q2 Sales: Grew 11.2% to EUR 798 million (USD 813 million).
- H1 2022 Sales: Increased 12.4% to EUR 1.699 billion (USD 1.730 billion).
Key Drivers in China
- Dupixent and Praluent (alirocumab): Benefited from recent National Reimbursement Drug List (NRDL) listings.
- Plavix (clopidogrel): Sales rose 19.1% to EUR 125 million (USD 127.3 million) due to volume-based procurement (VBP) tender success.
Diabetes Business Challenges
- VBP Impact: Insulin glargine (Toujeo/Lantus) inclusion in Round 6 of the VBP program led to a 24.2% drop in Q2 diabetes sales to EUR 101 million.
- H1 2022 Diabetes Sales: Down 5.3% to EUR 294 million. Sanofi expects annual sales in China to decline by 30% this year but noted that increased volume sales are offsetting price cuts.-Fineline Info & Tech
